Get the Stockscreener App
77.81
0.35%
0.27
After Hours:
77.81
Halozyme Therapeutics Inc stock is traded at $77.81, with a volume of 1.48M.
It is up +0.35% in the last 24 hours and up +13.48% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$77.54
Open:
$77.42
24h Volume:
1.48M
Relative Volume:
0.83
Market Cap:
$9.23B
Revenue:
$1.51B
Net Income/Loss:
$348.84M
P/E Ratio:
27.98
EPS:
2.7805
Net Cash Flow:
$667.65M
1W Performance:
+2.11%
1M Performance:
+13.48%
6M Performance:
+9.27%
1Y Performance:
+34.61%
1-Day Range:
$77.17
$79.56
1-Week Range:
$73.89
$79.56
52-Week Range:
$55.64
$82.26
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
77.81 | 9.20B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-25 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Technical Reactions to HALO Trends in Macro Strategies - Stock Traders Daily
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics (0J2O) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment - Yahoo Finance
HALO5387960 Bond Profile — Key Metrics - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 10% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) Q1 2025 earnings summary - Quartr
Halozyme Therapeutics (HALO) Proxy filing Summary - Quartr
Halozyme Therapeutics (HALO) Q1 2026 earnings summary - Quartr
Halozyme Therapeutics (HALO) AGM 2026 Summary - Quartr
2 Reasons to Like HALO and 1 to Stay Skeptical - Yahoo Finance
Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% Upside - TradingView
Halozyme president & CEO Helen Torley sells $153,390 in stock - Investing.com UK
Form 4 Halozyme Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Halozyme president & CEO Helen Torley sells $153,390 in stock By Investing.com - Investing.com Nigeria
Halozyme (HALO) CEO sells 1,923 exercised shares under Rule 10b5-1 plan - Stock Titan
How Halozyme’s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - simplywall.st
Halozyme Therapeutics focuses on drug-delivery partnerships as investors watch Nasdaq biotech sentim - ad-hoc-news.de
Halozyme Therapeutics (HALO) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Halozyme Therapeutics (HALO) Investor Outlook: Analyzing Growth with 42.20% Revenue Surge - DirectorsTalk Interviews
Halozyme's Q4 earnings miss, higher royalties drive Y/Y revenues - MSN
Halozyme signs collaboration deal with GSK for oncology targets - Investing.com
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued - Sahm
Price to sales forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Halozyme Therapeutics Operating Chief Caudill to Exit - Moomoo
Halozyme announces key executive leadership transition and reorganization - The Globe and Mail
Halozyme stock falls as chief operating officer departs By Investing.com - Investing.com Nigeria
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Halozyme stock falls as chief operating officer departs - Investing.com
Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting - Stock Titan
Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package - Stock Titan
Halozyme (HALO) director sells 1,625 shares in 10b5-1 trades - Stock Titan
Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle - Stock Titan
Halozyme Therapeutics, Inc. Announces Departure of Cortney Caudill as Senior Vice President, Chief Operating Officer - marketscreener.com
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative? - Sahm
Halozyme names David Ramsay as president drug delivery - Investing.com UK
Halozyme names David Ramsay as president drug delivery By Investing.com - Investing.com South Africa
Halozyme director Mahesh Krishnan sells $547,800 in stock By Investing.com - Investing.com South Africa
Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia
Halozyme director Mahesh Krishnan sells $547,800 in stock - Investing.com UK
Halozyme (HALO) director exercises options, sells 7,304 shares under plan - Stock Titan
Press Release: Halozyme Appoints David Ramsay as President Drug Delivery - Moomoo
Small Cap Core Portfolio I's Halozyme Therapeutics Inc(HALO) Holding History - GuruFocus
[144] HALOZYME THERAPEUTICS, INC. SEC Filing - Stock Titan
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Strong Revenue Growth and Promising Upside for Investors - DirectorsTalk Interviews
Price to sales forward of Halozyme Therapeutics, Inc. – FWB:RV7 - TradingView
Price to sales forward of Halozyme Therapeutics, Inc. – BMV:HALO - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (NASDAQ:HALO) - TradingView
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Jul 08 '26 |
Sale |
79.77 |
1,923 |
153,391 |
767,780 |
| RAMSAY DAVID A | EVP, PRESIDENT, DRUG DELIVERY |
Jun 30 '26 |
Option Exercise |
0.00 |
10,000 |
0 |
10,000 |
| Connaughton Bernadette | Director |
Jul 01 '26 |
Sale |
76.71 |
1,625 |
124,651 |
42,044 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Option Exercise |
38.46 |
7,304 |
280,912 |
21,766 |
| Krishnan Mahesh | Director |
Jun 29 '26 |
Sale |
75.00 |
7,304 |
547,800 |
14,462 |
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):